Alcoholism Clinical Trial
Official title:
Comparison of a Fixed-Schedule Therapy Versus a Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome in Medical Out-Patients
The purpose of this study is to compare a fixed-schedule therapy versus a symptom-triggered
therapy for alcohol withdrawal syndrome in medical outpatients.
Objectives:
- Self-governance in monitoring AWS (alcohol withdrawal syndrome) symptoms and medication
- Clinically controlled trial of two regimens for medical treatment of alcohol withdrawal
syndrome
- Outpatient treatment of alcohol withdrawal syndrome
The objective of this study is to compare a fixed-schedule therapy versus a
symptom-triggered therapy for alcohol withdrawal syndrome in medical outpatients.
Objectives:
- Self-governance in monitoring AWS (alcohol withdrawal syndrome) symptoms and medication
- Clinically controlled trial of two regimens for medical treatment of alcohol withdrawal
syndrome
- Outpatient treatment of alcohol withdrawal syndrome
Patients and Methods:
This study is a prospective analysis of patients admitted to a medical outpatient clinic
between August 25, 2003 and July 1, 2006, who experienced AWS. This study is conducted at
Copenhagen Hospital Corporation in Copenhagen, Denmark. Patients were divided into two
randomized groups: a symptom-triggered treatment versus a fixed-schedule treatment (known)
with chlordiazepoxide. They were diagnosed with AWS according to DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders Fourth Edition). They were diagnosed with alcohol
dependence according to the ICD-10 (International Statistical Classification of Diseases and
Health Related Problems).
Methods:
One hundred fifty consecutive patients who fulfill the inclusion criteria and not the
exclusion criteria were offered to participate in the study, i.e. also patients who were
detoxified at home or during admission. Patients were scored according to the DSM-IV for AWS
and ICD-10 for alcohol dependence, and then they filled out a SAWS (Short Alcohol Withdrawal
Scale). The score of 12 was the significant number of splitting patients to mild or moderate
AWS. Randomization was done by the Research Unit. Patients were then treated with the
traditionally fixed-schedule therapy (day 1, 200mg, chlordiazepoxide decreasing with 25 mg a
day) or the new symptom-triggered therapy (up to 300 mg, chlordiazepoxide a day). For up
until 10 days, patients monitored themselves for all ten days according to the SAWS. They
were asked about mental conditions day 1-14 and every third month using the World Health
Organization (WHO)-5 schedule.
On day 10 they filled out an adverse reactions questionnaire on chlordiazepoxide and a DTSQ
(Diabetes Treatment Satisfaction Questionnaire) and an ASI (Addiction Severity Index) every
third month.
Relapses and intake of any alcohol during a year are monitored.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT00536146 -
The Stress-Hormone System in Alcohol-Dependent Subjects
|
N/A | |
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Completed |
NCT01389297 -
Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery
|
N/A | |
Completed |
NCT01113164 -
Matching Genotypes and Serotonergic Medications for Alcoholism
|
Phase 1 | |
Completed |
NCT01760785 -
Valproate for Mood Swings and Alcohol Use Following Head Injury
|
N/A | |
Completed |
NCT00768508 -
Combined Pharmacotherapies for Alcoholism
|
Phase 3 | |
Completed |
NCT00127231 -
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
|
N/A | |
Terminated |
NCT02842528 -
Cognitive Vulnerability Factors in Alcohol-dependence
|
N/A | |
Completed |
NCT00367575 -
An Internet-based Intervention for Problem Drinking
|
N/A | |
Completed |
NCT00167687 -
Prazosin Alcohol Dependence IVR Study
|
Phase 4 | |
Completed |
NCT00223639 -
New Medications to Treat Alcohol Dependence
|
Phase 2 | |
Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 |